About Acalabrutinib API
Categoría Terapéutica Oncology
Número CAS
870524-78-5
Tecnología del API
Molécula pequeña
Forma de Dosificación
Sólido Oral/Cápsulas
Estado de Desarrollo en Dr. Reddy’s
En desarrollo
Mechanism of Action
Acalabrutinib is a Bruton tyrosine kinase (BTK) inhibitor. BTK is a protein that plays an important role in the survival and growth of B cells. By blocking BTK, acalabrutinib can help to slow down or even stop the growth of cancer cells.
Indication
The FDA approved Acalabrutinib for the treatment of adult patients with Mantle Cell Lymphoma (MCL) has received at least one prior therapy. Chronic lymphocytic leukemia (CLL). Small lymphocytic lymphoma (SLL).
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
